Novartis towards the spin-off and listing of the generic drugs division

Listen to the audio version of the article

Novartis AG investigates the spin-off of its generics unit and a possible listing. On the other hand, the sale to a buyout fund at the moment seems more complicated to carry out and the Swiss pharmaceutical giant is therefore considering a separate listing of the Sandoz business. An operation that could have the value of 25 billion dollars, according to Bloomberg. To date, the Novartis group has an overall market value of approx 200 billion dollars …